drugset / Trial / NCT00951574

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

NCT00951574 ↗

Phase 3 Completed 1166 enrolled Italfarmaco
RandomizedCrossoverQuadruple-blindPrevention

Summary

In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).

Timeline

Start
2003-10
Primary completion
2007-05
Completion
2008-07

Outcome

Met primary endpoint

paper 15 (2.0%) of 769 patients treated with nadroparin and 15 (3.9%) of 381 patients treated with placebo had a thromboembolic event (single-sided p=0.02). PMID 19726226 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Nadroparin Calcium Other / unclassified 3800 iu Subcutaneous